Today's Hot Stocks To Watch: COO, DLTR, and MDB
The decline in shares of MongoDB (MDB) potentially ended. Shares peaked in December 2024 at over $360. The descent accelerated when the firm posted quarterly results in March.Earlier this week MongoDB posted first-quarter revenue momentum. Revenue increased by 22% Y/Y to $549 million. Adjusted EPS was $1.06. MongoDB Atlas drove revenue after it rose by 26% Y/Y. Short-sellers who bet against the stock at $180 - $200 made a costly mistake. MDB stock closed at $225.38.In retail, Dollar Tree (DLTR) erased most of Wednesday’s loss. Shares gained 9.08% after J.P. Morgan praised the company for its tariff mitigation efforts. The analyst, Matthew Boss, thinks those efforts will more than offset short-term costs. As a result, shareholders should expect the company to achieve EPS growth in the double-digit percentage.Cooper Companies (COO) is forming a bottom this week. The stock gained 5.58% to close at $71.18. In the second quarter, organic revenue grew by 7%. Demand for its daily silicone hydrogel lens and the strong performance in the surgical portfolio are catalysts.Investors may also consider Alcon (ALC).Watch for Cooper Companies to work down their excess inventory. Customers, retailers, and distributors are careful with their spending levels.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


